Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression
NCT00554398
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
69
Enrollment
OTHER
Sponsor class
Conditions
HIV Infections
Interventions
DRUG:
MK-0518 400mg twice a day
Sponsor
Germans Trias i Pujol Hospital
Collaborators
[object Object]